Multiple law firms filed a securities fraud class-action lawsuit against ADMA Biologics, Inc. The complaint alleges the company issued misleading statements and failed to disclose critical information regarding internal controls.
The lawsuit centers on an alleged channel stuffing scheme used to inflate revenue growth. It also cites an undisclosed related-party transaction.
Legal action followed a March 2026 short-seller report. ADMA Biologics shares plummeted 29% over two trading days following the report's release.
Investors have until August 10, 2026, to seek the role of lead plaintiff.